Patents by Inventor Jochen Probst
Jochen Probst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338579Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.Type: ApplicationFiled: September 7, 2022Publication date: October 26, 2023Applicant: CureVac SEInventors: Mariola FOTIN-MLECZEK, Aleksandra KOWALCZYK, Regina HEIDENREICH, Patrick BAUMHOF, Jochen PROBST, Karl-Josef KALLEN
-
Publication number: 20230210965Abstract: The present invention relates to novel prime-boost regimens that involve the administration of at least one mRNA construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen.Type: ApplicationFiled: December 19, 2022Publication date: July 6, 2023Applicant: CureVac SEInventors: Mariola FOTIN-MLECZEK, Jochen PROBST
-
Patent number: 11661634Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: GrantFiled: July 21, 2022Date of Patent: May 30, 2023Assignee: CureVac Manufacturing GmbHInventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
-
Publication number: 20230158131Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.Type: ApplicationFiled: August 24, 2022Publication date: May 25, 2023Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Karl-Josef KALLEN, Jochen PROBST
-
Publication number: 20230053382Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: July 21, 2022Publication date: February 23, 2023Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Patent number: 11559570Abstract: The present invention relates to prime-boost regimens that involve the administration of at least one mRNA construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen. The present invention further describes methods, uses, vaccination compositions, kits and packaged vaccine components related to or useful for one or more of such regimens.Type: GrantFiled: May 13, 2016Date of Patent: January 24, 2023Assignee: CureVac SEInventors: Mariola Fotin-Mleczek, Jochen Probst
-
Publication number: 20220401555Abstract: The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.Type: ApplicationFiled: June 29, 2022Publication date: December 22, 2022Applicant: CureVac AGInventors: Thomas KRAMPS, Söhnke VOSS, Jochen PROBST, Ingmar HOERR
-
Publication number: 20220372158Abstract: The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.Type: ApplicationFiled: July 19, 2022Publication date: November 24, 2022Applicant: CureVac AGInventors: Ingmar HOERR, Jochen PROBST, Steve PASCOLO
-
Patent number: 11458195Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.Type: GrantFiled: August 29, 2019Date of Patent: October 4, 2022Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jochen Probst
-
Patent number: 11421038Abstract: The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.Type: GrantFiled: January 8, 2008Date of Patent: August 23, 2022Assignee: CureVac AGInventors: Ingmar Hoerr, Jochen Probst, Steve Pascolo
-
Publication number: 20220154253Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Publication number: 20220096616Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.Type: ApplicationFiled: July 19, 2021Publication date: March 31, 2022Applicant: CureVac AGInventors: Marijke BARNER, Jochen PROBST, Thomas LANDER, Ingmar HOERR
-
Patent number: 11268157Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: GrantFiled: June 2, 2020Date of Patent: March 8, 2022Assignee: CureVac Real Estate GmbHInventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
-
Publication number: 20210393755Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: ApplicationFiled: August 3, 2021Publication date: December 23, 2021Applicant: CureVac AGInventors: Andreas THESS, Thomas SCHLAKE, Jochen PROBST
-
Patent number: 11110156Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: GrantFiled: June 7, 2018Date of Patent: September 7, 2021Assignee: CureVac AGInventors: Andreas Thess, Thomas Schlake, Jochen Probst
-
Publication number: 20210128716Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: ApplicationFiled: December 31, 2020Publication date: May 6, 2021Applicant: CureVac AGInventors: Andreas THESS, Thomas SCHLAKE, Jochen PROBST
-
Publication number: 20210060181Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g. for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein.Type: ApplicationFiled: September 14, 2020Publication date: March 4, 2021Applicant: CureVac AGInventors: Andreas THESS, Thomas SCHLAKE, Jochen PROBST
-
Patent number: 10918740Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.Type: GrantFiled: July 19, 2018Date of Patent: February 16, 2021Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Aleksandra Kowalczyk, Regina Heidenreich, Patrick Baumhof, Jochen Probst, Karl-Josef Kallen
-
Patent number: 10912826Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: GrantFiled: July 24, 2020Date of Patent: February 9, 2021Assignee: CureVac AGInventors: Andreas Thess, Thomas Schlake, Jochen Probst
-
Patent number: 10898589Abstract: The present disclosure concerns a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. The present disclosure further concerns a method for increasing the expression of a peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: GrantFiled: February 19, 2018Date of Patent: January 26, 2021Assignee: Cure Vac AGInventors: Andreas Thess, Thomas Schlake, Jochen Probst